Clinical trials: sponsored by Asan Medical Center
Gastrointestinal Stromal Tumors (GISTs)
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Randomized, placebo-controlled, phase III study of regorafenib 160 mg once daily on intermittent dosing schedule of 3 weeks on treatment followed by 1 weeks off demonstrated the significant benefit of regorafenib in terms of PFS…
- Trial name
- NCT02889328
- Testing
- Regorafenib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Asan Medical Center
Sarcoma, Gastrointestinal Stromal Tumors
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
The presence of c-kit mutation is an independent poor prognostic factor for relapse in addition to large size (> 5 cm) and high mitotic rate (> 5/50 high power field [HPF]) in localized gastrointestinal stromal tumor (GIST)…
- Trial name
- NCT00278876
- Testing
- Imatinib mesylate (Glivec)
- Where
- 4 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Gastric Cancer
Study of XELOX With Cetuximab in Advanced Gastric Cancer
The combination of capecitabine and oxaliplatin as 'backbone' regimen, adding a newer biologic agent, cetuximab, is a reasonable strategy of further chemotherapy development in advanced gastric cancer, which is the investigators…
- Trial name
- NCT00398398
- Testing
- Capecitabine, Oxaliplatin, Cetuximab
- Where
- 3 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
Stomach Neoplasm
RAD001 (Everolimus) Salvage Monotherapy in Advanced Gastric Cancer (AGC) Who Failed Standard First-line Treatment
This is a phase II study to evaluate RAD001 (Everolimus) in terms of 4-month progression-free survival rate (primary end-point) and response rate, toxicity, and overall survival (secondary end-points) in patients with metastatic…
- Trial name
- NCT00729482
- Testing
- RAD001
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS
The urgent need for a new effective therapy with better safety profile for the metastatic gastric cancer patients and promising results observed so far in the studies with S-1 plus cisplatin combination in advanced gastric cancer…
- Trial name
- NCT00915382
- Testing
- S-1 and cisplatin
- Where
- South Korea
- Volunteers
- 625 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST): Nilotinib PK
In patients who are receiving nilotinib, nilotinib plasma levels will be measured after 1 month of nilotinib treatment. The relationship between surgery type and nilotinib pharmakokinetic properties will be investigated in this…
- Trial name
- NCT00976612
- Testing
- Nilotinib
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
Biweekly FOLFIRI in Advanced Gastric Cancer (AGC) With Failure of Prior Taxane, Fluoropyrimidine, and Cisplatin
The purpose of this study is: To observe the feasibility of biweekly oxaliplatin and infusional 5-fluorouracil (FU)/Leucovorin (LV) in patients with advanced gastric adenocarcinoma who have prior exposure to taxane…
- Trial name
- NCT00976768
- Testing
- oxaliplatin, 5-fluorouracil
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Asan Medical Center
Resected Advanced Gastric Cancer
Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer: Adjuvant DXP
Despite the improvement of surgical resection as primary curative treatment for gastric cancer, more than 70% of patients with stage IIIB and IV disease undergoing radical primary tumor resection relapse and die within 5 years.
- Trial name
- NCT00976976
- Testing
- docetaxel, capecitabine, cisplatin
- Where
- South Korea
- Volunteers
- 46 people
- Sponsor
- Asan Medical Center
Gastric Cancer, Histone Deacetylase Inhibitor
Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP
There is scientific rationale for exploring the role of vorinostat, histone deacetylase inhibitor with capecitabine (X) and cisplatin (P), one of standard chemotherapy in patients with advanced gastric cancer.
- Trial name
- NCT01045538
- Testing
- Vorinostat, capecitabine, and cisplatin
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
Venous Thromboembolism in Advanced Gastric Cancer Patients
Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is a common complication and leading cause of death in cancer patients.
- Trial name
- NCT01047618
- Where
- South Korea
- Volunteers
- 259 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
RAD001 in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer: RAD001+XELOX
It is expected that RAD001 works in gastric cancer by inhibiting PI3K/AKT/mTOR pathway and Hif1A (hypoxia inducible factor 1, alpha subunit), a key player in angiogenesis and the growth of tumors like renal cell…
- Trial name
- NCT01049620
- Testing
- RAD001, Capecitabine, Oxaliplatin
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Malignant Neoplasm of Stomach, Effects of Chemotherapy
Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation: STARGATE
This study investigates the efficacy and safety profiles of sorafenib in combination of capecitabine and cisplatin, one of standard chemotherapy regimens in patients with advanced gastric cancer.
- Trial name
- NCT01187212
- Testing
- Capecitabine/Cisplatin + Sorafenib, Capecitabine/Cisplatin
- Where
- South Korea
- Volunteers
- 195 people
- Sponsor
- Asan Medical Center
Metastatic or Recurrent Gastric Adenocarcinoma, Her-2 Positive Gastric Cancer
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
This is an open-label, multicentre, prospective phase II trial designed to evaluate the efficacy and safety of trastuzumab in combination with capecitabine and oxaliplatin as first-line therapy in patients with recurrent and/or…
- Trial name
- NCT01396707
- Testing
- Herceptin+XELOX
- Where
- South Korea
- Volunteers
- 55 people
- Sponsor
- Asan Medical Center
Advanced Gastric Cancer
Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer
The purpose of this study is to determine whether docetaxel, capecitabine, cisplatin, and bevacizumab are effective in the treatment of unresectable advanced gastric cancer.
- Trial name
- NCT01471470
- Testing
- Docetaxel, Capecitabine, Cisplatin, Bevacizumab
- Where
- South Korea
- Volunteers
- 31 people
- Sponsor
- Asan Medical Center
Stomach Neoplasm
RAD001 in Advanced Gastric Cancer Who Failed Standard First-line Treatment With pS6 Ser 240/4 Expression
This is a phase II study to evaluate RAD001 (Everolimus) in terms of 4-month progression-free survival rate (primary end-point) and response rate, toxicity, overall survival and biomarker assessment (secondary end-points) in…
- Trial name
- NCT01482299
- Testing
- RAD001
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Asan Medical Center
Gastric Cancer
Dovitinib for Gastric Cancer With FGFR2 Amplification: GASDOVI-1
This is a single-center, prospective, single-arm, open-label phase II study
- Trial name
- NCT01719549
- Testing
- Dovitinib
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
With discovery of KIT mutations and the advent of KIT tyrosine kinase inhibitor imatinib (GlivecTM, Novartis), there has been substantial improvement in overall survival in patients with advanced and/or metastatic…
- Trial name
- NCT02607332
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumor(GIST)
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe adverse event of imatinib in GIST patients and may…
- Trial name
- NCT03440515
- Testing
- Prednisone
- Volunteers
- 29 people
- Sponsor
- Asan Medical Center
Cancer-associated Thrombosis, Esophageal Cancer
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism
This is an open label, multi-center, and randomized phase II trial designed to compare the safety and efficacy of direct oral anticoagulants and subcutaneous dalteparin in patients with acute venous thromboembolism and upper…
- Conditions
- Cancer-associated Thrombosis, Esophageal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- PRIORITY (NCT03139487)
- Testing
- Rivaroxaban, Dalteparin, apixaban
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Asan Medical Center
Cerebral Arteries, Dissection
Prospective Observation for Serial Changes in Acute Intracranial Artery Dissection Using HR-MRI
Intracranial artery disease has been more detected with development of HR-MR. HR-MR can depict vascular wall directly and give us more information beyond the pre-existing imaging modalities such as digital subtraction…
- Trial name
- NCT03213470
- Testing
- magnetic resonance imaging
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center